RNAi Message Board - Msg: 22720798

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	8/15/2006 10:40:06 AM
	of 671

9:34AM Enzo Biochem reports long term retention of antisense RNA in Phase I study of HIV-1 infected subjects; updated report calls results "significant'' (ENZ) 11.14 : Co describes the results of long term follow-up studies of its StealthVector HGTV43 gene medicine as "significant" and "perhaps unique." HIV-1 infected subjects treated with the proprietary retrovirus-based vector showed long term presence of the engineered CD34+ stem cells as well as a long term presence of engineered CD4+ immune cells in circulation. The Phase I clinical trial took place at the University of California San Francisco. "These results are a significant, perhaps unique, example of the survival of engineered CD34+ stem cells in nonablated adult human subjects. That these engineered cells have produced progeny CD4+ immune cells is evidenced by the presence of antisense RNA in these cells in circulation."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next